Skip to Main Content

The drug giant Merck said Monday it would purchase Rockville, Md.-based OncoImmune for $425 million in cash to obtain the company’s treatment for patients hospitalized with severe and critical Covid-19. 

In an interview with STAT, Merck’s head of research and development, Roger Perlmutter, said that clinical trials for the treatment, CD24Fc, were encouraging but that manufacturing could prove a challenge. Still, he said, he hopes that, if proven safe and effective, it will be possible to make the medicine in useful quantities in the first half of 2021.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!